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In this retrospective study of hepatitis C virus (HCV)–infected transplant recipients in the 9-center Adult to Adult Living Donor
Liver Transplantation Cohort Study, graft and patient survival and the development of advanced fibrosis were compared among
181 living donor liver transplant (LDLT) recipients and 94 deceased donor liver transplant (DDLT) recipients. Overall 3-year
graft and patient survival were 68% and 74% in LDLT, and 80% and 82% in DDLT, respectively. Graft survival, but not patient
survival, was significantly lower for LDLT compared to DDLT (P  0.04 and P  0.20, respectively). Further analyses
demonstrated lower graft and patient survival among the first 20 LDLT cases at each center (LDLT 20) compared to later
cases (LDLT  20; P  0.002 and P  0.002, respectively) and DDLT recipients (P  0.001 and P  0.008, respectively). Graft
and patient survival in LDLT 20 and DDLT were not significantly different (P  0.66 and P  0.74, respectively). Overall,
3-year graft survival for DDLT, LDLT 20, and LDLT 20 were 80%, 79% and 55%, with similar results conditional on survival
to 90 days (84%, 87% and 68%, respectively). Predictors of graft loss beyond 90 days included LDLT 20 vs. DDLT (hazard
ratio [HR]  2.1, P  0.04), pretransplant hepatocellular carcinoma (HCC) (HR  2.21, P  0.03) and model for end-stage liver
disease (MELD) at transplantation (HR  1.24, P  0.04). In conclusion, 3-year graft and patient survival in HCV-infected
recipients of DDLT and LDLT 20 were not significantly different. Important predictors of graft loss in HCV-infected patients
were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation. Liver Transpl 13:122-129, 2007.
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Hepatitis C virus (HCV)–related end-stage liver disease
is the leading indication for liver transplantation in the
United States. Adult-to-adult living donor liver trans-
plantation represents an important means of expand-
ing the donor pool, making transplantation available to
an increasing number of patients on the waiting list.
Prior reports of HCV-infected living donor liver trans-
plant (LDLT) recipients having a poorer graft outcome
than HCV-infected deceased donor liver transplant
(DDLT) recipients have raised concerns regarding this
donor option for HCV-infected persons.1-5 In a study of
764 LDLT and 1,470 matched DDLT recipients trans-
planted between 1998 and 2001, the overall risk of graft
failure was 60% higher in LDLT recipients compared to
DDLT recipients (hazard ratio [HR]  1.6; 95% confi-
dence interval, 1.1, 2.5) after adjusting for baseline
differences in the groups such as serum creatinine,
United Network for Organ Sharing medical urgency sta-
tus, and need for life support.4 In HCV-positive pa-
tients, a similar pattern was seen of significantly lower
graft survival in LDLT compared with DDLT recipients.
In contrast, a second study from the United Network for
Organ Sharing database found no significant difference
in the 2-year graft survival between 279 LDLT and
3,955 DDLT recipients transplanted between 1999 and
2002 with a diagnosis of chronic HCV (P  0.21).5
Several theories have been proposed to explain differ-
ences in HCV recurrence in LDLT vs. DDLT recipients.
The rapid liver regeneration occurring in the early post-
transplant period in recipients of living donor grafts
may alter early virologic or immunologic events and
thereby affect the risk of progressive liver disease. Also,
live donor recipients are more likely than deceased do-
nor recipients to share human leukocyte antigens and
although the relationship between human leukocyte
antigens matching and risk of recurrent HCV is contro-
versial, it represents another difference between LDLT
recipients and DDLT recipients that may affect HCV
disease recurrence. Alternatively, because LDLT donors
typically are younger and the ischemia times are
shorter than with DDLT donors, outcomes may be bet-
ter among recipients of LDLT than of DDLT. At the
present time, these proposed mechanisms for an al-
tered natural history of HCV infection in recipients of
LDLT vs. DDLT remain speculative.
The Adult-to-Adult Living Donor Liver Transplantation
Cohort Study (A2ALL) is a consortium of 9 U.S. liver
transplant centers performing adult-to-adult LDLT with
the primary goal of examining outcomes of adult-to-adult
LDLT vs. DDLT. Both retrospective and prospective stud-
ies are ongoing, aimed at garnering information on donor
and recipient outcomes of LDLT over the decade from
1998 to 2008. In the present study, the retrospective
A2ALL cohort was used to compare graft and patient sur-
vival and the risk of advanced fibrosis in HCV-infected
recipients who underwent either LDLT or DDLT.
PATIENTS AND METHODS
Study Population
The A2ALL retrospective cohort includes 819 adult pa-
tients who had a potential living donor evaluated be-
tween January 1, 1998 and February 28, 2003. Inclu-
sion required that a patient’s potential donor undergo
an initial history and physical examination. HCV infec-
tion was defined by serologic and virologic tests avail-
able prior to transplantation. Among these potential
recipients, 382 had HCV infection. Excluding the HCV
patients who never went to the operating room for
transplantation (n  94), those who went to the oper-
ating room but whose transplant procedure was
aborted (n  8), those who received deceased donor
split liver transplantation (n  4), and those who re-
ceived a domino liver transplant (n  1), we studied the
275 HCV patients who received either a LDLT or a whole
DDLT. Patients with hepatocellular carcinoma (HCC)
were included. The HCV patients who received a LDLT
were compared to those who received a whole DDLT.
Data were abstracted from the clinical records at
each site. For specific variables, including date of
death, information from the Scientific Registry of Trans-
plant Recipients was used to augment data available in
A2ALL. Immunosuppression protocols, indications for
liver biopsy, treatment of rejection, and treatment of
recurrent HCV infection were not standardized across
centers. Virological data were incomplete and therefore
not used in the analyses. HCV genotypes were available
for 57% of patients; HCV RNA measurements were
available for 59% prior to transplantation. The labora-
tory model for end-stage liver disease (MELD) score was
calculated at the time of transplantation, and values
were capped at 40.6 Cold ischemia time was defined as
the interval from the donor cross-clamp to graft removal
from ice. Acute rejection was defined by the require-
ment for antirejection treatment whether or not rejec-
tion was biopsy proven. Biliary complications included
leaks and strictures identified by operative, endoscopic,
or radiological studies.
The primary study endpoint was graft survival, and
all causes of graft loss were included; death was re-
garded as a graft loss. Since graft loss within the first 90
days after transplantation was unlikely to be secondary
to HCV, both overall graft survival and graft survival
beyond 90 days were considered. Additionally, prior
A2ALL analyses of graft survival for all indications
found that the risk of graft failure was strongly associ-
ated with the number of previous LDLTs performed at a
given center. Examination of this effect by 5-case incre-
ments found that the first 20 LDLT cases at a center
had an increased risk of graft loss, compared to cases
beyond the first 20.7 Thus, graft survival among the
first 20 LDLT cases at each center (LDLT 20) was
compared with later cases (LDLT 20).
Secondary endpoints included patient survival and
liver biopsy evidence of HCV disease. Liver histology
was assessed by a single pathologist at each center
using a standardized scoring system. Pathologists were
blinded to patient outcomes. The modified Knodell hep-
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atitis activity index was used to measure necroinflam-
matory activity,8 and the Ishak score was used to as-
sess fibrosis.9 Biopsies lacking Knodell and Ishak
scores and those occurring more than 2 weeks after the
start of treatment for HCV were excluded. “Advanced”
histological disease was defined as an Ishak fibrosis
score greater than or equal to 3. In analyses of the time
to advanced disease, biopsies occurring less than 30
days after transplant and those without Ishak score
available were excluded.
The study was approved by the Institutional Review
Boards and Privacy Boards of each of the 9 participat-
ing transplant centers and the University of Michigan
Data Coordinating Center.
Statistical Analysis
Descriptive statistics included median, mean, standard
error, and range as appropriate. Comparisons of recip-
ient characteristics, donor characteristics, immuno-
suppression, and posttransplant complications be-
tween LDLT and DDLT recipients were performed using
chi-square tests for categorical variables and 2-sample
t tests for continuous variables. Graft and patient sur-
vival were estimated by the Kaplan-Meier method, and
unadjusted comparisons were made using the log-rank
test. The study sample size provides 90% power to de-
tect an HR 2.0 (for LDLT compared to DDLT) for either
graft or patient survival, assuming a 2-sided log-rank
test with alpha  0.05. Cox regression was used to
adjust for the effects of potentially confounding vari-
ables. The predictor variable of primary interest was
donor type (LDLT vs. DDLT). Overall graft survival and
survival limited to grafts surviving beyond the first 90
days posttransplantation were considered. Addition-
ally, graft survival among the first 20 LDLT cases at
each center (LDLT 20) was compared with later cases
(LDLT 20). Other potential confounders tested in the
Cox regression models were recipient age, recipient
gender, recipient race/ethnicity, donor age, donor gen-
der, year of transplantation (before or during 2000 vs.
after 2000), presence of HCC, pretransplant MELD
score, cold ischemia time, initial use of tacrolimus, and
initial use of mycophenolate mofetil. In addition, the
following variables were entered and tested in the Cox
model as time-varying covariates: prednisone use at 3
months posttransplantation, treated acute rejection,
acute rejection requiring antibody therapy, antiviral
therapy, and biliary complications. The interaction be-
tween immunosuppression and acute rejection was
evaluated.
We estimated the probability of Ishak score 3 by the
Kaplan-Meier method, and we tested for a difference
between LDLT and DDLT using a log-rank test, al-
though biopsy data were inconsistently collected. Biop-
sies occurring more than 2 weeks after start of treat-
ment for HCV were censored at that time. All analyses
were performed using SAS/STAT 9.1 User’s Guide (SAS
Publishing, Cary, NC).
RESULTS
A total of 275 patients in the A2ALL Retrospective Co-
hort Study had HCV infection and underwent liver
transplantation, 181 having received an LDLT and 94
having received a DDLT. The median follow-up post-
transplantation was 3.25 years (3.66 in LDLT and 2.78
in DDLT recipients). Two-thirds (65.5%) of patients
were transplanted prior to institution of MELD-based
DDLT allocation (76.8% of LDLT and 43.6% of DDLT,
P  0.0001). The majority of transplant recipients were
Caucasian (91%), 68% were male, and the median age
of the cohort was 51.1 years. HCC was present in 23%
of the patients. The baseline characteristics of the
DDLT and LDLT recipients are shown in Table 1. The
laboratory MELD score at the time of transplantation,
the proportion of male donors, and the cold ischemia
times were significantly higher in DDLT recipients than
TABLE 1. Pretransplant and Peritransplant Recipient and Donor Characteristics
LDLT (n  181)
Median (range)
or n (%)
DDLT (n  94)
Median (range)
or n (%) P Value*
Recipient age (years) 50.5 (29–71) 52.3 (30–74) 0.17
Male recipients 119 (66) 68 (72) 0.27
Caucasian recipients 166 (92) 84 (89) 0.52
Patients with pre-LT HCC 36 (20) 27 (29) 0.10
Laboratory MELD at transplantation† 14.0 (6–40) 18.0 (7–40) 0.0001
Donor age (years) 37.7 (19–57) 41.0 (9–72) 0.07
Male donors‡ 90 (50) 52 (63) 0.03
Cold ischemia time (minutes) 46.0 (5–480) 399.0 (12–600) 0.0001
Abbreviation: LT, liver transplant.
*For continuous variables (recipient and donor age, MELD, cold ischemia time), the P value is based on a 2-sample t test
comparing LDLT and DDLT; for dichotomous variables (% male, % Caucasian, % with HCC), the P value is based on a
chi-square test comparing LDLT and DDLT.
†Range from 6 (lowest risk) to 40 (highest risk).
‡Excludes 11 DDLT with missing donor gender.
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in LDLT recipients. DDLT recipients were older, had
older donors, and were more likely to have hepatocel-
lular carcinoma than LDLT recipients, but these differ-
ences were not statistically significant. Of those pa-
tients with HCC, 47.6% had tumors within Milan
criteria (a single lesion 5 cm in diameter, or no more
than 3 lesions 3 cm in diameter) and 52.4% (61.1% of
LDLT and 40.7% of DDLT) had tumors outside the Mi-
lan criteria.
Immunosuppression was similar between DDLT and
LDLT recipients. The majority of patients received tacroli-
mus (76.2% of LDLT recipents and 78.7% of DDLT recip-
ients), mycophenolate mofetil (61.3% of LDLT and 56.4%
of DDLT recipients) and prednisone (86.2% of LDLT and
89.4% of DDLT recipients) as baseline immunosuppres-
sion. The rate of treated acute rejection was 47.0% of
LDLT recipients compared to 37.2% of DDLT recipients
(P  0.16), and the median time to first episode of rejec-
tion was 14 days among LDLT recipients with at least 1
rejection, compared to 23 days among DDLT recipients
with at least 1 rejection (P  0.39). The use of antibody
therapy (OKT3 or thymoglobulin) for treatment of acute
rejection was higher in LDLT vs. DDLT recipients (25.9%
vs. 11.4% of treated rejection episodes), but this difference
was not statistically significant (P  0.08). The frequency
of biliary complications was significantly higher in LDLT
recipients, occurring in 39.2%, compared to 20.2% of
DDLT recipients (P  0.0014).
Graft and Patient Survival
Recipients of LDLT had a significantly lower cumulative
graft survival than recipients of DDLT in unadjusted
analysis (P  0.040, log-rank test). Cumulative patient
survival rates were not significantly different between
LDLT and DDLT recipients (P  0.20, log-rank test). The
primary causes of graft loss in the LDLT and DDLT
recipients are listed in Table 2. Recurrent HCV was the
primary or secondary cause of graft loss in 10 (5.5%) of
the 181 LDLT recipients and in 2 (2.1%) of the 94 DDLT
recipients (P  0.19).
Subsequent analyses, with the LDLT recipients di-
vided into the first 20 patients (LDLT 20, n  78) and
subsequent patients (LDLT 20, n  103) at each cen-
ter, revealed a significant difference in rates of graft
survival between LDLT 20 and DDLT (P  0.0007) and
between LDLT 20 and LDLT 20 (P  0.0023), but not
between DDLT and LDLT 20 (P  0.66) (Fig. 1). The
cumulative graft survival for DDLT, LDLT 20, and
LDLT 20 recipients was 87%, 84%, and 72% at 1 year,
respectively, and 80%, 79%, and 55% at 3 years, respec-
tively. Similarly cumulative graft survival beyond the first
90 days after transplantation was significantly lower in
LDLT 20 compared to LDLT 20 (P  0.021) and DDLT
(P  0.052), but there was no difference in graft survival
between LDLT 20 and DDLT (P  0.74) (Fig. 2). The
cumulative survival of grafts that survived beyond the
Figure 1. Graft survival after DDLT (dotted line), LDLT 20
(dashed line; first 20 cases at each center), and LDLT >20
(solid line; cases beyond the first 20 at each center). Graft
survival was significantly lower in LDLT 20 compared to
LDLT >20 (P  0.0023) and DDLT (P  0.0007). However,
there was no significant difference in graft survival between
LDLT >20 and DDLT (P  0.66, log-rank test).
Figure 2. Graft survival after DDLT (dotted line), LDLT 20
(dashed line; first 20 cases at each center), and LDLT >20
(solid line; cases beyond the first 20 at each center) condi-
tioned on graft survival to at least 90 days. Differences in
graft survival were seen in LDLT 20 compared to LDLT >20
(P  0.021) and DDLT (P  0.052), but there was no signifi-
cant difference in graft survival between LDLT >20 and DDLT
(P  0.74, log-rank test).







Recurrent HCV 8 (24) 2 (33)
Recurrent HCC 1 (3) 0 (0)
Vascular complications 7 (21) 0 (0)
Primary nonfunction 7 (21) 0 (0)
Infection 3 (9) 2 (33)
Biliary complications 2 (6) 1 (17)
Other 6 (18) 1 (17)
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first 90 days for DDLT, LDLT 20, and LDLT 20 recip-
ients was 91%, 93%, and 86% at 1 year, respectively, and
84%, 87%, and 68% at 3 years, respectively.
Patient survival in LDLT 20 was significantly lower
than both LDLT 20 (P  0.002) and DDLT (P  0.008).
However, patient survival in LDLT 20 and DDLT were
not significantly different (P  0.74). The cumulative
patient survival for DDLT, LDLT 20, and LDLT 20
recipients was 87%, 91%, and 78% at 1 year, respec-
tively, and 82%, 84% and 63% at 3 years, respectively.
Predictors of Graft and Patient Survival
Factors associated with significantly lower overall graft
survival in univariable analysis included LDLT 20, older
recipient age at transplantation, pretransplant diagnosis
of HCC, higher laboratory MELD score at transplantation,
the use of antibody therapy for treatment of acute rejec-
tion, and lack of tacrolimus use. In multivariable analysis,
only recipients of LDLT 20, older recipient age, pretrans-
plant diagnosis of HCC, higher laboratory MELD score at
transplantation, and rejection requiring antibody as a
time-varying covariate were significant independent pre-
dictors of lower graft survival (Table 3). For graft survival
beyond the first 90 days, only LDLT 20, pretransplant
HCC, and higher MELD at transplantation were indepen-
dent predictors of graft loss (Table 3).
Factors associated with significantly lower overall pa-
tient survival and patient survival beyond the first 90
days in multivariable analysis, were recipients of LDLT
20, pretransplant diagnosis of HCC, and higher labora-
tory MELD score at transplantation (Table 4). There was
no difference in patient survival among HCV patients with
HCC within Milan criteria compared to those with HCC
outside Milan criteria (HR  1.15; 95% confidence inter-
val, 0.46, 2.87; P  0.76). Among the 20 patients with
HCC who died, recurrent HCC was the primary cause of
death in 4 patients (20%) and recurrent HCV was the
primary cause of death in 2 patients (10%).
TABLE 3. Predictors of Overall Graft Loss and Graft Loss Beyond First 90 Days*
Predictor Variable
Overall Graft Survival Graft Survival Beyond 90 Days
HR (95% CI) P Value HR (95% CI) P Value
LDLT 20 vs. DDLT† 3.04 (1.66, 6.64) 0.001 2.11 (1.02, 4.37) 0.045
LDLT 20 vs. DDLT† 1.49 (0.77, 2.88) 0.238 1.17 (0.53, 2.54) 0.70
Recipient age (per 10 years) 1.37 (1.01, 1.86) 0.043 1.22 (0.82, 1.80) 0.326
Pre-LT HCC 1.89 (1.08, 3.32) 0.027 2.21 (1.10, 4.42) 0.025
Laboratory MELD at LT
(per 5 points)
1.26 (1.07, 1.48) 0.006 1.24 (1.01, 1.54) 0.044
Tacrolimus at baseline 0.71 (0.42, 1.20) 0.201 0.67 (0.34, 1.29) 0.225
Rejection requiring antibody‡ 2.36 (1.10, 5.06) 0.028 1.88 (0.72, 4.89) 0.198
Abbreviation: CI, confidence interval.
*Variables tested but not significant (P  0.10) in the multivariable Cox regression model: donor age, cold ischemia time, biliary
complications (time-varying covariate) and antiviral treatment (time-varying covariate).
†LDLT 20 are those LDLTs performed among the first 20 at a given center. LDLT 20 are those LDLTs performed after at least
20 LDLTs had been performed at the given center.
‡Time-varying covariate.
TABLE 4. Predictors of Overall Patient Death and Patient Death Beyond First 90 Days*
Predictor Variable
Overall Patient Survival
Patient Survival Beyond 90
Days
HR (95% CI) P Value HR (95% CI) P Value
LDLT 20 vs. DDLT† 2.66 (1.42, 4.50) 0.002 2.56 (1.25, 5.23) 0.010
LDLT 20 vs. DDLT† 1.34 (0.67, 2.69) 0.404 1.37 (0.63, 2.96) 0.428
Recipient age (per 10 years) 1.37 (0.99, 1.91) 0.058 1.18 (0.81, 1.71) 0.387
Pre-LT HCC 2.24 (1.23, 4.06) 0.008 2.30 (1.19, 4.46) 0.013
Laboratory MELD at LT (per 5 points) 1.30 (1.09, 1.55) 0.003 1.27 (1.04, 1.55) 0.021
Tacrolimus at baseline 0.64 (0.37, 1.10) 0.108 0.76 (0.40, 1.44) 0.399
Abbreviation: CI, confidence interval.
*Variables tested but not significant (P  0.10) in the multivariable Cox regression model: donor age, cold ischemia time,
rejection requiring antibody (time-varying covariate), biliary complications (time-varying covariate), and antiviral treatment
(time-varying covariate).
†LDLT 20 are those LDLTs performed among the first 20 at a given center. LDLT 20 are those LDLTs performed after at least
20 LDLTs had been performed at the given center.
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Among LDLT recipients, graft to body weight ratio
was not predictive of graft or patient survival.
Histological Severity of Disease
A total of 138 patients (82 LDLT and 56 DDLT) had at
least 1 biopsy that could be evaluated for severity of
HCV disease at some point posttransplantation, with a
median duration of histological follow-up of 12 months
(range, 0.03 to 59 months). The proportion of patients
with a biopsy evaluated for HCV disease severity varied
from 33% to 95% at the different study sites. Of the 224
patients with a functioning graft at 1 year posttrans-
plantation, 63 (28%; 36 LDLT, 27 DDLT) had liver bi-
opsies available at 1 year  4 months that could be
evaluated for recurrent HCV disease severity. In pa-
tients receiving HCV treatment, histology was assessed
using biopsies up to 2 weeks following treatment start.
There was no significant difference in the total necroin-
flammatory (P  0.19) or fibrosis scores (P  0.93)
between DDLT and LDLT recipients at 1 year posttrans-
plantation (Table 5).
Treatment of HCV was undertaken in 32% of DDLT
and 34% of LDLT (P  0.70). In a time-to-event analysis
restricted to the 123 patients with a biopsy at least 30
days posttransplantation and no more than 2 weeks
after the initiation of HCV treatment, the time required
to progress to an Ishak fibrosis score of 3 was not
different for LDLT vs. DDLT recipients (P  0.87, unad-
justed log-rank test) (Fig. 3).
DISCUSSION
In this multicenter U.S. study, we show that the out-
comes of HCV-infected patients with LDLT are not sig-
nificantly different from DDLT recipients once trans-
plant centers have sufficient experience with LDLT.
Prior studies examining the effects of LDLT on HCV
outcomes failed to take “experience of the transplant
program with LDLT” into account, likely contributing to
the divergence in reported outcomes. The reasons for
the difference in outcomes of HCV-infected live donor
transplant recipients early in a center’s experience vs.
later are not completely clear. However, most trans-
plant physicians recognize the unique technical chal-
lenges in performing living donor transplants in adults,
and several publications attest to the higher rate of
graft loss early in the posttransplant period related to
vascular problems, biliary complications, and small-
for-size syndrome.10,11 These technical issues have
great relevance in the first 90 days posttransplantation.
However, the observation that graft survival remains
lower in recipients of LDLT 20 than in recipients of
LDLT 20 or DDLT even beyond that time point sug-
gests that ongoing complications resulting from early
events ultimately affect graft longevity. Given the find-
ings in our study, future studies evaluating outcomes
in HCV-infected LDLT patients will need to consider the
effect of “center experience.”
TABLE 5. Liver Disease Severity Evaluated by Liver Biopsy
LDLT DDLT P-Value
Duration of histologic follow-up (median, range), months* 12.7 (8.2–32) 13.3 (8.3–52) 0.22
Knodell HAI score at 1 year  4 months (median, range)† 3.5 (0–12) 5 (1–12) 0.19
Ishak fibrosis score at 1 year  4 months (n, %)† 0.93
0–2 30 (83.3%) 23 (85.2%)
3–6 5 (13.9%) 3 (11.1%)
Abbreviation: HAI, hepatitis activity index.
*A total of 138 patients (82 LDLT and 56 DDLT) had at least 1 biopsy.
†Of the 224 patients with a functioning graft at 1 year posttransplantation, 63 (28%; 36 LDLT, 27 DDLT) had liver biopsies
available at 1 year  4 months that could be evaluated for HCV disease severity. In patients receiving HCV treatment,
histology was assessed on the biopsy occurring no more than 2 weeks after start of treatment for HCV. Three DDLT recipients
had missing Knodell HAI scores, and 1 LDLT recipient and 1 DDLT recipient had missing Ishak fibrosis score. Knodell HAI
score includes necroinflammatory components only (maximum possible score, 18).
Figure 3. A total of 123 patients had at least 1 biopsy that
occurred 30 days posttransplantation and no more than 2
weeks after the start of HCV treatment and had an Ishak
fibrosis score. The cumulative risk of Ishak fibrosis score of 3
or more (bridging fibrosis or cirrhosis) on biopsy was not
significantly different among LDLT 20 (solid line; n  28),
LDLT >20 (dashed line; n  43), and DDLT (dotted line; n 
52) groups (P > 0.05 for all comparisons by log-rank test,
unadjusted). Patients were censored at time of treatment of
HCV disease.
LDLT OR DDLT OUTCOMES IN HCV-INFECTED RECIPIENTS 127
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
While recurrent HCV infection is essentially universal
following transplantation, the rate of histologic disease
progression is quite variable. Multiple factors have been
linked with worse histological disease, including donor
age, HCV genotype, cold and warm ischemia times,
treated acute rejection, cytomegalovirus infection, and
pretransplant HCV viral load.12-15 Whether or not re-
cipients of a living-donor liver transplant have an in-
creased risk of recurrent cirrhosis is a question of great
interest. The 2 largest protocol biopsy studies, 1 from
the United States and 1 from Spain, reported quite
disparate results. In a U.S. study of 23 LDLT and 53
DDLT patients, patient and graft survival was not dif-
ferent, and there was no patient with cirrhosis in either
group after a median follow-up of 40 months.16 In con-
trast, in a Spanish study using protocol liver biopsies,
cirrhosis or liver decompensation occurred in 44% of
LDLT patients compared with 29% of DDLT patients
(P  0.019).2 In the present study, the proportion of
LDLT recipients with advanced fibrosis, defined as an
Ishak fibrosis score of 3 or greater at 1 year posttrans-
plantation, was 14.3% compared to 11.5% in DDLT (P 
0.75). Similarly, the rate of progression to advanced
fibrosis was not different between LDLT and DDLT re-
cipients. While supportive of our overall results regard-
ing graft survival, cautious interpretation of the histo-
logical data are needed, since protocol biopsies were not
used and only 28% of patients had biopsies that could
be evaluated for recurrent disease at 1 year posttrans-
plantation. Clearly, prospective studies utilizing proto-
col liver biopsies to assess disease severity are the op-
timal means of determining whether there is a
difference in disease progression and severity between
LDLT and DDLT recipients. This is a primary aim of the
prospective A2ALL Cohort Study currently underway.
The incidence of HCC is increasing, reflecting, in part,
the increasing number of persons with HCV and cirrho-
sis.17 Liver transplantation is the treatment of choice
for patients with cirrhosis and small HCCs.18 In this
cohort, nearly a quarter of the liver transplant recipi-
ents with HCV infection had HCC as an additional di-
agnosis. Timely transplantation of patients with limited
HCC is critical in maximizing good outcomes and in
preventing recurrent HCC. Recently, MELD exception
scores for HCC were modified, as data showed that
prior prioritization points for HCC were unfairly favor-
ing access to DDLT for these patients. LDLT is also an
important option for patients with limited HCC and may
allow patients’ access to liver transplantation in a time
interval shorter than for DDLT, thereby reducing the
rate of drop-off from the list due to tumor progression.
Alternatively, more rapid access to transplantation in
patients with tumors at the limits of current United
Network for Organ Sharing criteria may allow patients
with more aggressive tumor biology and a higher risk of
recurrence to be transplanted when they would other-
wise have become noncandidates due to tumor progres-
sion if DDLT were utilized. In our study, a pretransplant
diagnosis of HCC was an independent predictor of re-
duced overall patient survival beyond 90 days. This
observation may be related to the inclusion of patients
with more advanced stages of HCC. We did not find a
significant difference in overall risk of death in patients
with tumors inside vs. outside of the Milan criteria (P 
0.76). However, it is noteworthy that the majority of
patients in this cohort were transplanted prior to the
routine use of aggressive ablative treatment of HCC in
patients on the waiting list for transplantation and prior
to the implementation of the MELD HCC exception pol-
icy.
There are recognized limitations of this study. As this
was a retrospective study, data on virologic aspects of
HCV disease, such as genotype and HCV viral load,
were inconsistently collected and measured. However,
we do not believe this limitation would have biased the
results. Most studies indicate that genotype is not pre-
dictive of survival,19-21 and pretransplant HCV viral
loads did not influence the decision of whether or not to
perform LDLT. Additionally, immunosuppression and
treatment of acute rejection were not standardized, and
the indications for liver biopsies varied from center to
center. These differences in posttransplant manage-
ment may have contributed to differences in graft out-
come. Nevertheless, since LDLT and DDLT recipients
came from the same centers, differential bias in immu-
nosuppression and acute rejection strategies by donor
type may have been reduced. Finally, the median dura-
tion of follow-up was relatively short (3 years), and
differences in graft losses due to recurrent HCV be-
tween LDLT 20 and DDLT may become evident with
long-term follow-up. However, the strengths of our
study are the large number of LDLT recipients evalu-
ated, the inclusion of LDLT from multiple large trans-
plant centers to minimize center-specific biases, and
the ability to validate key variables using Scientific Reg-
istry of Transplant Recipients data.
In conclusion, this study demonstrates that graft
survival is not significantly different for recipients of
LDLT compared to DDLT once centers have sufficient
experience with LDLT. Thus, HCV-infected patients
awaiting transplantation should not be denied LDLT if
an appropriate living donor is available.
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